Skip to content

Comparing outcomes of vaginal delivery with Paily Forceps against a vacuum device

A single-blinded randomised clinical trial to determine the effectiveness and safety of Paily obstetric forceps vs ventouse in operative vaginal delivery.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13034177
Enrollment
100
Registered
2022-05-25
Start date
2006-08-01
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effectively conducting operative vaginal delivery and preventing maternal or neonatal injuries in term ( = 37 weeks) mothers. Pregnancy and Childbirth

Interventions

This randomised clinical trial is conducted in the Department of Obstetrics and Gynecology, Mother Hospital, Thrissur, from August 2006 to November 2007, over 16 months. Mother hospital has an annual

Sponsors

Mother Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Pregnant women above 18 years of age. 2. Term pregnancy (=37 completed weeks of gestational age) 3. Cephalic presentation 4. Fully dilated and fully effaced cervix 5. Ruptured membranes 6. Fetal head at +2 station or lower (Low or Outlet station) 7. Fetal head rotation =45° 8. Clinically adequate pelvis 9. Clinically indicated instrumental delivery: 9.1. Maternal indications: 9.1.1. Prolonged second stage of labor 9.1.2. Maternal exhaustion 9.1.3. Elective application to shorten second stage of labor 9.1.3.1. Medical diseases like cardiac diseases (NYHA Grade 3 or 4), severe pre-eclampsia, hypertensive crises, cerebrovascular malformation, myasthenia gravis, and spinal cord injury. 9.1.3.2. Vaginal Birth After Cesarean Delivery (VBAC) 9.2. Fetal Indications 9.2.1. Fetal Distress in second stage as determined by non-reassuring fetal heart rate pattern or Grade 3 meconium passage 9.2.2. Prolapsed umbilical cord 9.2.3. Premature separation of placenta.

Exclusion criteria

Exclusion criteria: 1. Participant refused to participate in trial/ no informed consent provided 2. Patients with bleeding diathesis

Design outcomes

Primary

MeasureTime frame
Success rate of instrumental delivery - calculated by the ratio of deliveries not requiring a second-line intervention (another instrument or subsequent caesarean delivery) to the total number of instrumental delivery

Secondary

MeasureTime frame
All safety analyses will be conducted on an “As-treated” basis. 1. Incidence of Maternal adverse events: 1.1. During the second and third stages of labour: 1.1.1. Episiotomy extension 1.1.2. Cervix laceration 1.1.3. Vaginal laceration 1.1.4. Perineal laceration 1.1.5. Paraurethral laceration 1.1.6. Third and Fourth-degree perineal lacerations 1.1.7. Post-partum haemorrhage (>500 ml of blood loss) 1.2. Fourth stage and puerperium 1.2.1. Need for blood transfusion 1.2.2. Urinary retention 1.2.3. Urinary tract infection 1.2.4. Episiotomy hematoma 1.2.5. Anemia 1.2.6. Need for antibiotics 1.2.7. Duration of hospitalization 2. Neonatal outcomes and adverse events: 2.1. APGAR score at 1st and 5th minute 2.2. Liquor (Clear/ Grade-1/Grade-2/Grade-3) 2.3. Caput succedaneum 2.4. Scalp, facial bruising or injuries 2.5. Cephalhematoma 2.6. Sub-galeal hematoma 2.7. Neonatal jaundice 2.8. Cerebral edema 2.9. Sub-conjunctival hemorrhage 2.10. 6th and 7th brachial plexus injury 2.11. Clavicle fracture 2.12. Intraventricular hemorrhage 2.13. Neonatal Intensive care unit stay 2.14. Hospital stay 2.15. Neonatal death

Countries

India

Contacts

Public ContactManu Pradeep
drmanupradeep24@gmail.com+91 9947568919

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026